ProCE Banner Activity

CheckMate 9LA: 4-Yr Update of First-line Nivolumab + Ipilimumab + CT vs CT Alone in Advanced NSCLC

Conference Coverage
Slideset

Long-term update of CheckMate 9LA study of first-line nivolumab plus ipilimumab and CT in patients with advanced NSCLC continues to demonstrate durable OS, PFS, and DoR improvement vs CT alone, with consistent clinical benefit across subgroups.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure